Entourage effect

Abstrax Unveils the Intriguing Chemistry Behind Savory Cannabis Aromas

Retrieved on:

Monday, December 11, 2023

TUSTIN, Calif., Dec. 11, 2023 /PRNewswire-PRWeb/ -- Abstrax, the leader in botanical flavor technology, has released a new white paper that reveals paradigm-shifting insights into the origins of chemical and savory aromas in cannabis strains. Their latest research sheds more light on the complexity of cannabis aroma profiles and the specific compounds that influence them. Despite common belief, terpenes aren't responsible for the quintessentially dank or exotic aromas of cannabis.

Key Points:

TUSTIN, Calif., Dec. 11, 2023 /PRNewswire-PRWeb/ -- Abstrax , the leader in botanical flavor technology, has released a new white paper that reveals paradigm-shifting insights into the origins of chemical and savory aromas in cannabis strains.
Despite common belief, terpenes aren't responsible for the quintessentially dank or exotic aromas of cannabis.
- Max Koby, CEO of Abstrax
The chemical/savory varieties of cannabis, known for their unique and pungent aromas, have their olfactory roots in a compound known as skatole.
For more information about Abstrax and its groundbreaking research into cannabis aromas, visit https://abstraxtech.com/blogs/learn/the-science-of-exotic-cannabis-funky... .

New Study Shows That Aroma-Not THC-Drives the Cannabis Consumer Experience

Retrieved on:

Wednesday, November 16, 2022

HILLSBORO, Ore., Nov. 16, 2022 /PRNewswire-PRWeb/ -- In a new study published in the journal Psychoactives, some of the most influential minds in the industry today are breaking down the current understanding of what makes a "quality" cannabis experience. And to do so, they've done something even more groundbreaking: they've asked the consumer.

Key Points:

Groundbreaking new study led by True Terpenes Science Board members Dr. Ethan Russo and Jeremy Plumb shows correlation between cannabis aroma -- not THC -- and consumer enjoyment.
The study is revolutionary in its stated purpose: "to objectively identify features of cannabis that contribute to its appealing subjective effects."
In other words, to apply scientific methods to understanding what the consumer actually enjoys.
This study lays the groundwork for a redefinition of value, based on the enjoyment of the consumer, as reported by the consumer.

Charlotte's Web Signs Exclusive UK Distribution Agreement with Savage Cabbage

Retrieved on:

Monday, March 21, 2022

Savage Cabbage will be utilizing its extensive network in the UK to expand the presence of Charlotte's Web as the Novel Foods regulatory framework continues to progress.

Key Points:

Savage Cabbage will be utilizing its extensive network in the UK to expand the presence of Charlotte's Web as the Novel Foods regulatory framework continues to progress.
Jade Proudman is the founder and CEO of Savage Cabbage, who credits Charlotte's Web CBD Oil with "saving her life ".
She is an influential voice in the UK & European CBD community, while also being a Global Ambassador of Charlotte's Web.
Savage Cabbage has shared similar values as Charlotte's Web since inception and we are excited to start expanding our presence in the UK market beyond ecommerce," said Jacques Tortoroli, CEO of Charlotte's Web.

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc.

Retrieved on:

Thursday, March 17, 2022

The terms of the original agreement call for Havn Life Sciences to supply Mycotopia Therapies with naturally-derived psilocybin.

Key Points:

The terms of the original agreement call for Havn Life Sciences to supply Mycotopia Therapies with naturally-derived psilocybin.
In December 2021 Mycotopia Therapies Inc. announced it had entered into a letter of intent regarding a potential acquisition of botanical psilocybin pioneer, Ei.Ventures.
Mycotopia Therapies is focused on the research, development, and commercialization of novel therapeutics based on naturally-derived psilocybin.
Performing most of its research in Jamaica, where psilocybin is legal, Mycotopia Therapies is focused on mushroom and psychedelic opportunities.

Charlotte's Web Names Jade Proudman Global Brand Ambassador

Retrieved on:

Thursday, January 27, 2022

DENVER and LONDON, Jan. 27, 2022 /PRNewswire/ -- (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," or the "Company"), the market leader in full spectrum cannabidiol ("CBD") hemp extract wellness products , has named Jade Proudman, the Chief Executive Officer of Savage Cabbage, one of the oldest and most trusted CBD companies in the UK, as a Global Brand Ambassador for Charlotte's Web.

Key Points:

DENVER and LONDON, Jan. 27, 2022 /PRNewswire/ -- (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," or the "Company"), the market leader in full spectrum cannabidiol ("CBD") hemp extract wellness products , has named Jade Proudman, the Chief Executive Officer of Savage Cabbage, one of the oldest and most trusted CBD companies in the UK, as a Global Brand Ambassador for Charlotte's Web.
Mrs. Proudman credits Charlotte's Web with " saving her life " and has been helping others access the benefits of cannabinoid therapy through her work ever since.
Savage Cabbage distributes Charlotte's Web full spectrum CBD oils in the UK in alignment with its three founding pillars: Quality, Consistency and Reliability.
"For over six years, Jade has relentlessly focused on helping consumers in the UK and across Europe access the power of Charlotte's Web.

Charlotte's Web Names Jade Proudman Global Brand Ambassador

Retrieved on:

Thursday, January 27, 2022

DENVER and LONDON, Jan. 27, 2022 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," or the "Company"), the market leader in full spectrum cannabidiol ("CBD") hemp extract wellness products , has named Jade Proudman, the Chief Executive Officer of Savage Cabbage, one of the oldest and most trusted CBD companies in the UK, as a Global Brand Ambassador for Charlotte's Web.

Key Points:

DENVER and LONDON, Jan. 27, 2022 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," or the "Company"), the market leader in full spectrum cannabidiol ("CBD") hemp extract wellness products , has named Jade Proudman, the Chief Executive Officer of Savage Cabbage, one of the oldest and most trusted CBD companies in the UK, as a Global Brand Ambassador for Charlotte's Web.
Mrs. Proudman credits Charlotte's Web with " saving her life " and has been helping others access the benefits of cannabinoid therapy through her work ever since.
Savage Cabbage distributes Charlotte's Web full spectrum CBD oils in the UK in alignment with its three founding pillars: Quality, Consistency and Reliability.
"For over six years, Jade has relentlessly focused on helping consumers in the UK and across Europe access the power of Charlotte's Web.

The Hemp Doctor: Announcing a New Line of Delta 9 THC Gummies

Retrieved on:

Saturday, January 22, 2022

Solvent, Research, Hemp, Entourage effect, CBN, Xerostomia, CBD, GLOBE, Cannabinoid, THC, HHC, Oil, Space Delta 9, Delta

MOORESVILLE, N.C., Jan. 22, 2022 (GLOBE NEWSWIRE) -- The Hemp Doctor is proud and excited to announce its new Delta 9 THC Gummies.

Key Points:

MOORESVILLE, N.C., Jan. 22, 2022 (GLOBE NEWSWIRE) -- The Hemp Doctor is proud and excited to announce its new Delta 9 THC Gummies.
Hot on the heels of the THC-O vapes and gummies, as well as the HHC vape release, these Delta 9 THC gummies are unbeatable.
Finally, the party gummies, Delta 9 THC/Delta 8 THC Full Spectrum Gummies, are a perfect blend of D8 THC and D9 THC with a walloping 65 mg of THC.
The Hemp Doctor invites you to shop online and inspect their full line of Delta 9 THC products.

Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures

Retrieved on:

Wednesday, December 8, 2021

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to spin out 30% of its Mycotopia Therapies (OTC: TPIA) shares to existing shareholders on a pro rata basis. Mycotopia Therapies announced Tuesday it had signed an LOI with Ei.Ventures and that the two companies plan to explore a potential merger and formation of PSLY.COM, a $360 Million transaction. Once the transaction is completed, the combined companies will apply to list on NASDAQ.

Key Points:

Ehave controls approximately 9,793,754 shares of Mycotopia Therapies, and the Company plans to spin out a percentage of its shares of the combined companies to its existing shareholders.
Ehave acquired its shares in Mycotopia Therapies in December 2020 after its Board of directors elected to sell 100% of its Mycotopia Therapy subsidiary to 20/20 Global for $350,000 and 9,793,754 shares of 20/20 Global stock.
20/20 Global was renamed to Mycotopia Therapies and files audited financial statements with the U. S. Securities and Exchange Commission on EDGAR.
Mycotopia Therapies also plans to open psylocibin and ketamine clinics in Jamaica under the direction of a licensed clinical psychiatrist.

Mycotopia and Ei.Ventures sign LOI to Explore Merger and Formation of PSLY.COM, a $360 Million Transaction, And Will Apply To List Shares On NASDAQ

Retrieved on:

Tuesday, December 7, 2021

Ei.Ventures flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase.

Key Points:

Ei.Ventures flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase.
Ei.Ventures has pioneered using the whole plant and fungi in its botanical formulations, which has the potential to create the Entourage Effect.
Performing most of its research in Jamaica, where psilocybin is legal, Mycotopia Therapies is focused on mushroom and psychedelic opportunities.
Mycotopia Therapies also plans to open psylocibin and ketamine clinics in Jamaica under the direction of a licensed clinical psychiatrist.

Juva Life Launches Preclinical Comparative Study to Evaluate Anti-Inflammatory Properties of Candidate JUVA-019 in Conjunction With Other Well-Known Cannabinoids

Retrieved on:

Tuesday, November 30, 2021

The goal of the study is to determine if Juva will advance JUVA-019 as a standalone compound, or if it will combine with other cannabinoids as a drug candidate with anti-inflammatory properties.

Key Points:

The goal of the study is to determine if Juva will advance JUVA-019 as a standalone compound, or if it will combine with other cannabinoids as a drug candidate with anti-inflammatory properties.
This is an important step in the research protocol of our pharmaceutical program on JUVA-019, said Doug Chloupek, CEO and Founder of Juva.
While there is plenty of anecdotal evidence that cannabis holds anti-inflammatory properties, the true cause of the mode of action remains unknown.
Juva is working to bring the Cannabis market face to face with the sectors next generation investment grade business model.